The key drawback is the lack of Bodily evaluation, which can result in inaccuracy of prescription.  Its announcement arrives over the heels of a similar licensing arrangement offered in February to Adastra Labs, which had until finally now focused on crafting cannabis extracts. Adastra's license also allows it to supply and provide psilocybin and